Under a tenth of people eligible to benefit from weight-loss injections such as Wegovy are able to get them, warns the World Health Organization as it releases its initial guidance on the drugs.
With in excess of 1,000,000,000 individuals worldwide now obese, it is advocating for increased and just availability to this class of drugs.
Based on forecasts, more than two billion are projected to be obese by 2030 if no action is taken.
"The new guidelines acknowledges that excess weight is a lifelong illness that can be managed with comprehensive and ongoing support," remarked WHO director-general Tedros Adhanom Ghebreyesus.
High costs, limited production capacity, and distribution challenges are significant hurdles to broad access to the jabs that can assist patients in reducing substantial body mass, explains the organization.
Despite the present most optimistic case, the supply of these medications could only cover about 100 million people โ fewer than 10% of those who need them, as stated by the WHO.
The recommendation encourages countries and companies to expand availability, by strategies like voluntary licensing.
The intellectual property rights on a key compound โ the main component of a leading brand โ is due to expire in multiple nations in 2026.
The injections imitate a biological compound to reduce digestion speed, reduce hunger and enhance feelings of fullness so people eat less.
Patients commonly begin shedding pounds within a few weeks of commencing the once-weekly jabs.
Studies suggests people may see weight return a year later of stopping the medication, because their usual food cravings come back.
Being carrying excess weight increases your likelihood for experiencing medical conditions, including type 2 diabetes, cardiovascular issues, brain attack, and certain cancers.
Excess weight impacts individuals in countries worldwide and was associated with over three and a half million deaths worldwide in 2024, as per the WHO.